| Project item | Indications | Research phase | Cooperation demands |
| NSS-21001 | Cancer cachexia | Preclinical candidate compound identified | License-out or co-development. |
| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| IL6-Y65 | Mouse | Mouse IL-6 Antibody, Mouse IgG1 (1A11E2) | |||
| CRS-B001 | Human | ClinMax™ Human IL-6 ELISA Kit | |||
| EP-146 | Human | IL-6[Biotinylated] : IL-6 R alpha Inhibitor Screening ELISA Kit | |||
| CEA-C001 | Human | ClinMax™ Human IL-6 ELISA Kit, PRO | |||
| CRS-A005 | Human | Human Interleukin-6 (IL-6) ELISA Kit (Residue Testing) | |||
| IL6-C5249 | Cynomolgus | Cynomolgus IL-6 Protein, His Tag (MALS verified) |  |
|
|
| IL6-H82Q9 | Human | Biotinylated Human IL-6 Protein, Avitag™,His Tag |  |
|
|
| IL6-M82Q7 | Mouse | Biotinylated Mouse IL-6 Protein, Avitag™,His Tag |  |
|
|
| IL6-M5245 | Mouse | Mouse IL-6 Protein, His Tag |  |
|
|
| IL6-H8218 | Human | Biotinylated Human IL-6 Protein, epitope tag free, ultra sensitivity, primary amine labeling |  |
|
|
| IL6-H4218 | Human | Human IL-6 Protein, premium grade |  |
|
|
ACROBiosystems offers custom GMP-grade protein service based on your needs: select one of our non-GMP protein products to convert to GMP or we can develop a custom GMP-grade protein product from scratch to maximize your therapy's success.>>Click here to request GMP version now
Biotinylated Human IL-6, epitope tag free, primary amine labeling (Cat. No. IL6-H8218) stimulates proliferation of TF-1 human erythroleukemic cell line. The EC50 for this effect is 0.2532-0.4489 ng/mL (Routinely tested).
Loaded Biotinylated Human IL-6, epitope tag free, primary amine labeling (Cat. No. IL6-H8218) on SA Biosensor, can bind Human IL-6 R alpha, His Tag (Cat. No. ILR-H4223) with an affinity constant of 45.9 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Luminol sodium | MP-1032 | Approved | Selvim, Metrio | Psoriasis; Immune System Diseases | null | 1997-01-01 | Immune System Diseases; Psoriasis | Details | ||
| Siltuximab | cCLB-8; CNTO-328 | Approved | Johnson & Johnson | Sylvant | Mainland China | Multicentric Castleman's Disease (MCD) | Beigene (Beijing) Biotechnology Co Ltd | 2014-04-23 | Immunoglobulin Light-chain Amyloidosis; Leukemia, Large Granular Lymphocytic; Thrombocytopenia; Lymphoma, Non-Hodgkin; Lung Neoplasms; Primary Myelofibrosis; Colorectal Neoplasms; Castleman Disease; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Neoplasms, Plasma Cell; Prostatic Neoplasms; Multicentric Castleman's Disease (MCD); Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Kidney Neoplasms; Myelodysplastic Syndromes; Pancreatic Neoplasms; Smoldering Multiple Myeloma; Psychotic Disorders; Polycythemia Vera; Carcinoma, Renal Cell; Schizophrenia; Diabetes Mellitus, Type 1; Cytokine Release Syndrome; Head and Neck Neoplasms; Ovarian Neoplasms; Bone Marrow Neoplasms | Details |
| Pomalidomide | IMID-4047; CDC-394; CC-4047; IMiD-1 | Approved | Celgene Corp | Pomalyst, Imnovid, Actimid, Pomalyst/Imnovid, 安跃 | Mainland China | Multiple Myeloma | Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | 2013-02-08 | Pulmonary Fibrosis; Anemia, Sickle Cell; Atypical Squamous Cells of the Cervix; Neurofibromatosis 1; Sarcoma, Kaposi; Lymphoma, Non-Hodgkin; Carcinoma, Small Cell; Glioma; Waldenstrom Macroglobulinemia; Primary Myelofibrosis; Sarcoma; Prostatic Neoplasms; Thrombocytosis; Lung Diseases, Interstitial; Solid tumours; Central Nervous System Neoplasms; Multiple Myeloma; Hodgkin Disease; Scleroderma, Systemic; Pancreatic Neoplasms; Kidney Diseases; Immunoglobulin Light-chain Amyloidosis; Graft vs Host Disease; Myeloproliferative Disorders; Plasmacytoma; Polycythemia Vera; Medulloblastoma; Bone Marrow Neoplasms | Details |
| Lenalidomide | CC-5013; IMiD-3; ENMD-0997; STAR-LLD; CDC-501; IMID-5013; CDC-5013 | Approved | Celgene Corp | Revimid (former Brand Name), 瑞复美, Revlimid, Leavdo | EU | Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular | Celgene Europe Bv | 2005-12-27 | Leukemia; Leukemia, Myeloid; Immunoproliferative Small Intestinal Disease; Leukemia, Erythroblastic, Acute; Lymphoma, T-Cell, Peripheral; Lymphoma, B-Cell, Marginal Zone; Ovarian Neoplasms; Medulloblastoma; Intestinal Neoplasms; Bone Marrow Neoplasms; Solid tumours; Kidney Neoplasms; Liver Neoplasms; HIV Infections; Hematologic Diseases; Optic Nerve Glioma; Leukemia, Promyelocytic, Acute; Ependymoma; Anemia, Refractory, with Excess of Blasts; Plaque, Amyloid; Leukemia, Hairy Cell; Anemia; Paraproteinemias; Pain; Polycythemia Vera; Rhabdoid Tumor; Hodgkin Disease; Myelodysplastic Syndromes; Nerve Degeneration; Lymphomatoid Granulomatosis; Pancreatic Neoplasms; Smoldering Multiple Myeloma; Anemia, Refractory; Leukemia-Lymphoma, Adult T-Cell; Plasmacytoma; Lymphoma, Large B-Cell, Diffuse; Blood Protein Disorders; Neoplasms; Glioblastoma; Leukemia, Myelomonocytic, Chronic; Graft vs Host Disease; Hypothalamic Neoplasms; Myeloproliferative Disorders; Leukemia, Myelomonocytic, Acute; Urinary Bladder Neoplasms; Multi | Details |
| Thalidomide | NSC-66847; NSC-527179; K-17; VP-02 | Approved | Celgene Corp | Talizer, Thalidomide Celgene, Thalidomide Pharmion, Synovir, Thalomid, Thaled | Japan | Leprosy, Lepromatous | Fujimoto Pharmaceutical | 1982-01-01 | Osteosarcoma; Leprosy, Lepromatous; Drug Resistant Epilepsy; Primary Myelofibrosis; Neuroectodermal Tumors, Primitive; Prostatitis; Colorectal Neoplasms; Lymphoma, Mantle-Cell; Sarcoma, Ewing; Retinoblastoma; Waldenstrom Macroglobulinemia; Cholangitis, Sclerosing; HIV Wasting Syndrome; Arachnoiditis; Adenocarcinoma, Clear Cell; Prostatic Neoplasms; Pancreatitis, Chronic; Lymphoma, Follicular; Sarcoma; Xerostomia; Burning Mouth Syndrome; Neoplasm Metastasis; Mycobacterium avium-intracellulare Infection; Vascular Malformations; Amyotrophic Lateral Sclerosis; Melanoma; Carcinoma, Hepatocellular; Leukemia, Lymphocytic, Chronic, B-Cell; Myelodysplastic-Myeloproliferative Diseases; Stomatitis; Erythema Nodosum; Anemia, Sideroblastic; Uterine Neoplasms; Lymphoma, Non-Hodgkin; Glioma; Angiodysplasia; Pelvic Pain; Appendiceal Neoplasms; Lung Neoplasms; Endometrial Neoplasms; Mycobacterium Infections; Gastric Antral Vascular Ectasia; Carcinoid Tumor; Lupus Erythematosus, Discoid; Stomatitis, Aphthous; Rhabdomyosarcoma; | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Anti-interleukin-6 receptor monoclonal antibody (Biocad) | Phase 2 Clinical | Biocad | Autoimmune Diseases | Details | |
| Wogonin | Phase 1 Clinical | Shandong Buchang Pharmaceuticals Co Ltd, Hefei Cosource Medicine Technology, Daewoong Pharmaceutical Co Ltd, China Pharmaceutical University | Respiratory Tract Infections; Neoplasms | Details | |
| Mycobacterium cell wall-DNA Complex (ProMetic Life Sciences) | EN-3348 | Prometic Life Sciences | Details | ||
| MEDI-5117 | WBP-216; MEDI-5117 | Phase 1 Clinical | Wuxi Apptec Co Ltd, Medimmune | Arthritis, Rheumatoid | Details |
| PF-04236921 | PF-4236921; PF-04236921 | Pfizer Pharmaceuticals Ltd (China) | Details | ||
| Olokizumab | CDP-6038; Anti-IL6-UCB | Ucb | Details | ||
| Ensereptide | PXL-01 | Phase 3 Clinical | Promore Pharma | Post-surgical adhesions; Cicatrix | Details |
| FB-704A | FB-704; FB-704A | Phase 2 Clinical | Fountain Biopharma Inc | Arthritis, Rheumatoid; Asthma | Details |
| Isomyosamine | MYMD-1 | Phase 2 Clinical | Mymd Pharmaceuticals Inc | Depression; Anxiety; Hashimoto Disease; Coronavirus Disease 2019 (COVID-19); Healthy Aging; Inflammation | Details |
| Sirukumab | BA-003; CNTO-136 | Phase 2 Clinical | Glaxosmithkline Plc, Janssen Global Services Llc | Giant Cell Arteritis; Depressive Disorder, Major; Arthritis, Rheumatoid; Coronavirus Disease 2019 (COVID-19); Lupus Erythematosus, Cutaneous; Lupus Nephritis; Polymyalgia Rheumatica; Lupus Erythematosus, Systemic; Asthma | Details |
| Monoclonal Antibody (Mab) sB24M | Phase 1 Clinical | Swiss Biopharma Med GmbH | Pyoderma Gangrenosum; Pyoderma | Details | |
| Efprezimod alfa | CD24-Fc; HAS-CD24; CD24-Fc-IgG; MK-7110; MK7110 | Phase 3 Clinical | Oncoimmune Inc | Leukemia; Hematopoietic stem cell transplantation (HSCT); HIV Infections; Solid tumours; Graft vs Host Disease; Coronavirus Disease 2019 (COVID-19); Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Dyslipidemias; Leukemia, Myeloid, Acute; Melanoma | Details |
| Clazakizumab | ALD-518; ALD518-003; BMS-645429; BMS-945429 | Phase 3 Clinical | Alder Biopharmaceuticals | Plaque, Atherosclerotic; Arthritis, Rheumatoid; Fatigue; Coronavirus Disease 2019 (COVID-19); Graft vs Host Disease; Rejection of organ transplantation; Arthritis, Psoriatic; Asthma; Cachexia; Carcinoma, Non-Small-Cell Lung; Crohn Disease; Stomatitis; Kidney Failure, Chronic | Details |
| RO-7200220 | RO-7200220 | Phase 2 Clinical | F. Hoffmann-La Roche Ltd | Diabetic macular oedema | Details |
| Tocilizumab biosimilar (Mycenax Biotech) | Phase 1 Clinical | Mycenax Biotech Inc | Arthritis, Rheumatoid | Details | |
| Ziltivekimab | COR-001 | Phase 3 Clinical | Astrazeneca Pharmaceutical Co Ltd | Heart Failure; Anemia; Cardiovascular Diseases; Renal Insufficiency, Chronic; Inflammation; Systemic Inflammatory Response Syndrome | Details |
| Gerilimzumab | GB-224; RYI-008; ARGX-109 | Phase 1 Clinical | Argenx Se | Arthritis, Rheumatoid | Details |
This web search service is supported by Google Inc.
A-Z
FLAG
Star Staining
ViruStop
Aneuro
ComboX
ActiveMax
GENPower
ClinMax 
Star Ribbon 
